Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.50 (2.82%)
Spread: 0.50 (2.778%)
Open: 17.75
High: 19.00
Low: 17.75
Prev. Close: 17.75
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

Wed, 25th Nov 2020 18:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

SourceBio International PLC - laboratory services and products firm - Says provides over 330,000 Covid-19 tests to UK Department of Health & Social Care. Continuing to build capacity for Covid-19 testing services and expects more demand in 2021. Expects annual revenue of GBP50 million, more than double GBP21.2 million in 2019. Forecasts earnings before interest, tax, depreciation and amortisation to surge to GBP14.0 million from GBP3.0 million. Renews testing services pact with Spire Healthcare Ltd.

----------

Nanoco Group PLC - Manchester-based quantum dots developer - Secures grant funding from UK innovation agency Innovate UK. Grant will go towards life sciences project to develop a quantum dot testing kit for rapid visual detection of Covid-19. "The project will cost just under GBP1.0 million to which the Innovate grant contributes 80% with the balance funded by Nanoco," company explains.

----------

Sensyne Health PLC - clinical artificial intelligence company - Signs five-year non-exclusive research agreement with Hampshire Hospitals NHS Foundation Trust which will probe the ethical application of artificial intelligence research to improve patient care and improve development of new medicines. Says trust will receive 1.1% Sensyne stake and Hampshire hospitals to receive GBP250,000 annual Sensyne invest over five-year term of research pact.

----------

Destiny Pharma PLC - clinical stage biotechnology company based in Brighton - Raises GBP870,000 from ipen offer, taking total fundraise to GBP10.4 million. "We are very pleased with the results of the fundraising and the support from our existing and new shareholders," CEO Neil Clark says.

----------

OPG Power Ventures PLC - Indian power plant operator - Collects about GBP9.5 million from contractual claims from customers under power purchase agreements. "The collection of these claims has strengthened the group's financial position and liquidity during these uncertain times caused by the Covid-19 pandemic," OPG says.

----------

IronRidge Resources Ltd - Africa-focused minerals explorer - Says additional test work completed at Ewoyaa project to improve lithium recoveries. Says "pleased" to have "refined recoveries and mass yields" without loss of concentrate grade.

----------

AEX Gold Inc - Greenland-focused gold miner - Says results from drilling at Nalunaq gold asset in Greenland support interpretation that Valley Block area is a "high-grade domain" similar to South Block. "We are very encouraged at the prospective nature of the Valley Block following the delivery of further interesting drilling results from this year's drilling campaign," Chief Executive Officer Eldur Olafsson says.

----------

Ncondezi Energy Ltd - operator of coal-fired power project in Mozambique - Raises GBP750,000 from oversubscribed placing of 16.7 million shares at 4.5p each.

----------

Pantheon Resources PLC - oil and gas exploration company focused on the Alaska North Slope - Reports rig contract secured with Nordic Calista Services to drill Talitha #A well. Operations to start in January.

----------

URU Metals Ltd - exploration and development - Raises GBP280,600 through subscription of 122,000 depositary interests at 230p each. "The proceeds of the equity placing will be used by the company for general working capital purposes," URU says.

----------

Xeros Technology Group PLC - Rotherham, South Yorkshire-based laundry and garment technology group - Says Indian license partner, Ramsons Garment Finishing Equipment Ltd receives order for nine denim finishing machines which use Xeros technology. "The order represents the first sales of Xeros' innovative XDrum design which fully automates the use of the group's proprietary XOrbs in garment finishing and laundry processes," Xeros says. "In line with the board's expectations, Xeros will receive a mid to high single digit royalty for these machine sales as well as royalties for the ongoing use of XOrbs."

----------

Gresham House Energy Storage Fund PLC - UK utility-scale battery storage fund - Raises GBP120 million through issue of 114.3 million shares at 105 pence each. Funds to go towards finance energy assets as part of 485 megawatt project pipeline being progressed by its manager.

----------

RDL Realisation PLC - debt instrument investor - Serves notice on alternative investment fund manager, International Fund Management Ltd and notifies UK Financial Conduct Authority it intends to become a self-managed AIFM, saving on external management fees. Changes to come into effect in February. Also says it will convene a general meeting to approve Main Market delisting, which it explains will unlock further cost savings.

----------

TMT Investments PLC - Jersey-headquartered technology companies investor - Enters into loan agreement with Macmillan Trading Co Ltd for USD5.0 million financing which incurs no interest and is repayable any time before December 31, 2021. This will allow TMT to continue making investments while waiting for USD41 million cash from Pipedrive Inc disposal.

----------

GlobalData PLC - market research firm - Says in 10 months ended October 31, revenue, excluding events, rose 5% year-on-year. Adjusted earnings before interest, tax, depreciation and amortisation up 12% during period. Expects flat annual revenue despite Covid-19 hurt.

----------

Argo Blockchain PLC - UK-based cryptocurrency miner - Says share capital reduction comes into effect. Share capital comprises 239.8 million shares.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.